Showing results (1251-1260 of 4,516) with videos related to

Sort By:
Pageof 452
Future Oncology (London, England)|April 10, 2020
Predictive markers of immune response in glioblastoma: hopes and factsVincenzo Di Nunno, Enrico Franceschi, Lidia Gatto, et al.
Future Oncology (London, England)|May 17, 2021
FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancerArvind Dasari, Alberto Sobrero, James Yao, et al.
Future Oncology (London, England)|August 19, 2021
Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancerDaniel J George, David P Dearnaley
Future Oncology (London, England)|August 19, 2021
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancerDavid M O'Malley, Leslie M Randall, Camille Gunderson Jackson, et al.
Future Oncology (London, England)|August 19, 2021
Solitary fibrous tumor: molecular hallmarks and treatment for a rare sarcomaAlannah Smrke, Khin Thway, Paul H Huang, et al.
Future Oncology (London, England)|August 11, 2021
Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018Shannon N Westin, Melinda Louie-Gao, Divya Gupta, et al.
Future Oncology (London, England)|August 24, 2022
HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinomaJosep Tabernero, Lin Shen, Elena Elimova, et al.
Future Oncology (London, England)|November 16, 2021
Radiomics features based on T2-weighted fluid-attenuated inversion recovery MRI predict the expression levels of CD44 and CD133 in lower grade gliomasZhenhua Wang, Xiaoping Tang, Ji Wu, et al.
Future Oncology (London, England)|November 17, 2021
Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trialsWenjing Li, Jingwei Jiang, Lizhen Huang, et al.
Future Oncology (London, England)|November 29, 2021
Plasma SNORD83A as a potential biomarker for early diagnosis of non-small-cell lung cancerKangyu Wang, Xingguo Song, Xinyi Li, et al.
Pageof 452